Condition: Advanced Cancer · Advanced Solid Tumor · Melanoma · Sponsor: 7 Hills Pharma, LLC
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens. Currently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study near completion of the Phase 1b
This description comes directly from the study's public registry record.
Sr. Director Clinical Affairs · 1.210.279.1998 · nicole@7hillspharma.com
VP Clinical Affairs and Regulatory · 6892623575 · bill@7hillspharma.com
Always discuss trial participation with your own doctor first.
| University of Colorado Cancer Center | Aurora, Colorado, United States | Recruiting |
| Florida Cancer Specialists | Lake Mary, Florida, United States | Completed |
| Dartmouth Hitchcock | Lebanon, New Hampshire, United States | Recruiting |
| Brown University Health Cancer Institute | Providence, Rhode Island, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06362369